Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Institute for Clinical and Experimental Medicine
Memorial Sloan Kettering Cancer Center
Rockefeller University
Massachusetts General Hospital
University of Wisconsin, Madison
Fred Hutchinson Cancer Center
University of California, San Francisco